Zivo Bioscience, Inc. Common Stock
ZIVO
ZIVO was delisted on the 24th of November, 2023.
12 hedge funds and large institutions have $1.42M invested in Zivo Bioscience, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 6 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
71% more capital invested
Capital invested by funds: $829K → $1.42M (+$590K)
0% more funds holding
Funds holding: 12 → 12 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.19M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$270K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$88.9K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$80.1K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$8.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$206K |
| 2 |
Jane Street
New York
|
-$191K |
| 3 |
Two Sigma Investments
New York
|
-$143K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$138K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$34.7K |
ZIVO Hedge Fund Activity: Q4 2021 in Review
12 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Zivo Bioscience, Inc. Common Stock (ZIVO) for Q4 2021, worth a combined $1.42M — up 71% from $829K a quarter earlier.
Fund positioning in ZIVO was balanced in Q4 2021: 6 funds opened new positions, 6 closed out, 3 added to existing stakes and 1 trimmed.
The largest buyer was Geode Capital Management, opening a new position worth an estimated $1.19M. The largest seller was Credit Suisse, exiting entirely with an estimated $206K sold.
- 12 institutional investors held Zivo Bioscience, Inc. Common Stock (ZIVO) as of Q4 2021, unchanged from Q3 2021.
- Funds reported $1.42M of Zivo Bioscience, Inc. Common Stock stock for Q4 2021, up 71% quarter-over-quarter.
- 6 funds opened new Zivo Bioscience, Inc. Common Stock positions in Q4 2021 and 6 closed out, a net change of 0 holders.
- The largest Zivo Bioscience, Inc. Common Stock buyer in Q4 2021 was Geode Capital Management, an estimated $1.19M added.
- The largest Zivo Bioscience, Inc. Common Stock seller in Q4 2021 was Credit Suisse, an estimated $206K sold.
Based on aggregated 13F filings for Q4 2021.